High risk (HR) pediatric oncology patients continue to undergo new and emerging treatment protocols, which have multiple complications that patients may encounter. Accurate assessment and early interventions is key to supporting patients through therapy. This session will focus on supportive cares for relapse leukemia and HR neuroblastoma patients; with special focus on the immunotherapy drugs blinatumomab and dinutuximab as well as infection prophylaxis. Most frequent serious adverse events noted in patients treated with blinatumomab are disorders of the nervous system and systemic cytokine release syndrome (CRS). Events are usually reversible and able to be managed with attentive supportive care. Most frequent side effects noted in patient treated with dinutuximab are pain, hypersensitivity reactions, CRS, capillary leak, fevers, and hypotension. We will use case studies of HR patients.
- Creating a Pediatric Hematology/Oncology Manuscript to Submit for Publication in a Nursing Journal (003)
- Opening Keynote: Never Ever Give Up! (101)
- General Session: Oral Medicine for Pediatric Hematology/Oncology Nursing (102)
- Going Viral: Review of Viral Illness and Antiviral Therapy in Hematopoietic Stem Cell Transplant Pediatric Patients (200)
- Management of Retinoblastoma in 2018: A Nursing Perspective (201)